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Abstract 
Meta-analyses confirm that depression is accompanied by signs of inflammation including 
increased levels of acute phase proteins, e.g. C-reactive protein, and pro-inflammatory cytokines, 
e.g. interleukin-6. Supporting the translational significance of this, a meta-analysis showed that 
anti-inflammatory drugs may have antidepressant effects. Here we argue that inflammation and 
depression research needs to get onto a new track. Firstly, the choice of inflammatory biomarkers 
in depression research was often too selective and did not consider the broader pathways. 
Secondly, although mild inflammatory responses are present in depression, other immune-related 
pathways cannot be disregarded as new drug targets, e.g. activation of cell-mediated immunity, 
oxidative and nitrosative stress (O&NS) pathways, autoimmune responses, bacterial 
translocation, activation of the Toll-like Receptor and neuroprogressive pathways. Thirdly, anti-
inflammatory treatments are sometimes used without full understanding of their effects on the 
broader pathways underpinning depression. Since many of the activated immune-inflammatory 
pathways in depression actually confer protection against an overzealous inflammatory response, 
targeting these pathways may result in unpredictable and unwanted results. Furthermore, this 
paper discusses the required improvements in research strategy, i.e. path and drug discovery 
processes, omics-based techniques and systems biomedicine methodologies. Firstly, novel 
methods should be employed to examine the intracellular networks that control and modulate the 
immune, O&NS and neuroprogressive pathways using omics-based assays, including genomics, 
transcriptomics, proteomics, metabolomics, epigenomics and microbiomics. Secondly, systems 
biomedicine analyses are essential to unravel the complex interactions between these cellular 
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networks, pathways and the multifactorial trigger factors and to delineate new drug targets in the 
cellular networks or pathways. Drug discovery processes should delineate new drugs targeting 
the intracellular networks and immune-related pathways. 
 
Key words: depression, immune, inflammation, neuroprogression, oxidative and nitrosative 
stress, leaky gut, IDO, TRYCATs 
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Introduction 
 Depression, either unipolar or bipolar depression, is a life-long systemic and 
multifactorial disorder. Until recently, major elements of its pathophysiology were largely 
unknown and therefore targeted treatments (outside the monoamines) could not be developed. 
Classical antidepressants, which target monoamine systems, show a clinical efficacy that is only 
marginally better than placebo [1]. Recent meta-analyses summarize that depression is 
accompanied by mild systemic inflammation including increased levels of inflammatory 
cytokines, e.g. interleukin (IL)-6, IL-1 and tumor necrosis factor (TNF)α, and signs of an acute 
phase response [2,3]. Recently, a systematic review and a meta-analysis showed that anti-
inflammatory drugs may have antidepressant effects [4,5]. The latter authors state that because 
there is an inflammatory state in depression, anti-inflammatory drugs were examined, and that 
the results of their meta-analysis are proof of concept that anti-inflammatory drugs are useful in 
depression. One of the major non-profit organizations supporting research on the causes of 
bipolar disorder, i.e. the Stanley Medical Research Institute, launched in 2014 a call to support 
research into the treatment of bipolar depression with anti-inflammatory drugs. Here it is 
contended that there are gaps in the way that inflammation in depression research is currently 
conceptualized and consequently we suggest a more powerful direction for future immune-
related depression research. 
 
Inflammation is not the only drug target in depression  
 As described by the Scientist (2003) “the first inkling that there is a connection between 
depression and inflammation came in 1990 when Michael Maes, a Belgian psychiatrist, reported 
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that depression is accompanied by an activation of the inflammatory response system”. 
Nevertheless, mild chronic inflammation [1,6,7] is only one very general concept in depression 
and describes its pathophysiology only superficially [8]. Since 1990, other and sometimes more 
important immune-related pathways were discovered, e.g. activation of cell-mediated immunity 
(CMI), including T cell activation, e.g. a T helper (Th)1 shift [9]; activation of oxidative stress 
pathways [10-12]; decreased levels of key antioxidants, including coenzyme Q10 [12,13]; 
hypernitrosylation [12,14]; autoimmune responses directed against oxidative and nitroso-specific 
epitopes [12,14]; increased bacterial translocation followed by increased immune responses to 
lipopolysaccharides (LPS) of gram negative bacteria [15]; and activation of the Toll-like 
Receptor (TLR) 2/4 Radical Cycle [16-19]. 
 Moreover, depression is characterized by immune-serotonin interactions, including 
activation of indoleamine 2,3-dioxygenase (IDO) with increased levels of tryptophan catabolites 
(TRYCATs) and lowered levels of tryptophan [20-22]; immune-endocrine interactions, including 
cytokine-associated glucocorticoid resistance [6,9]; and immune-metabolic (in particular lipids) 
interactions, including inverse associations between immune activation and lowered high density 
cholesterol,  3 polyunsaturated fatty acid (PUFAs) levels and the reverse cholesterol transport 
[11,23]. Interestingly, animal depression models based on psychosocial stress show that 
depression-like behaviors are associated with activated immune-inflammatory and oxidative and 
nitrosative stress (O&NS) pathways [24,25]. New animal models of depression have been 
developed based on chronic (repeated intermittent) administration of LPS and peripheral and 
central activation of the TLR complex and [26-28]. The latter studies suggest a bifunctional role 
of TLR-4 signaling pathway by triggering neuroinflammation at prefrontal cortex level and by 
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regulating gut barrier function and permeability [27,28]. Moreover they also show that bacterial 
translocation is responsible, at least in part, for the TLR-4 activation found in the brain after the 
exposure to the depression model [27,28]. 
 Finally, all abovementioned immune- and O&NS-related pathways and interactions may 
explain the presence of neuroprogressive processes in depression, that is neuronal changes 
including reduced bioenergetic mitochondrial functions, neuroplasticity and neurogenesis, cell 
signaling dysfunctions, apoptosis, etc. [29-32]. Immune-inflammatory, O&NS, autoimmune and 
neuroprogressive pathways are involved in shaping depressive phenomenology, staging of 
depression (e.g. treatment resistance, recurrence, chronicity and sensitization) and the 
comorbidity with many (neuro)inflammatory or (auto)immune disorders [29-32]. Shared immune 
and O&NS pathways in part explain the robust comorbidity of depression with medical 
conditions, e.g. a) cardiovascular disorder; chronic obstructive pulmonary disease; systemic 
lupus erythematosus; HIV infection; inflammatory bowel disease; obesity; the metabolic 
syndrome; diabetes type 2; rheumatoid arthritis; chronic kidney disease; alcohol dependence; 
tobacco use disorder; and b) central nervous system (CNS) disorders characterized by 
neuroinflammation, e.g. Alzheimer’s and Parkinson’s disease; multiple sclerosis; and stroke 
[33,34]. Moreover, depression when suffered with other medical and CNS disorders may 
increase morbidity and mortality of these comorbid disorders [34]. The postnatal period, 
interferon-(IFN)α-based immunotherapy, nicotine dependence, hemodialysis and psychosocial 
stressors (life events, chronic stress) are other immune- and O&NS-related conditions that may 
trigger the onset of depression in some vulnerable subjects [33,34]. 
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Gaps and required improvements: biomarkers 
 Measuring a few selected biomarkers, e.g. IL-6 without measurement of its soluble 
receptor (sIL-6R) or C-reactive protein (CRP), became the gold standard in inflammation and 
depression research [35,36]. However, appropriate acute phase protein biomarkers of clinical 
depression other than CRP were already established in the 1991-1992, e.g. haptoglobin, albumin 
and transferrin [2]. Nevertheless, most research focused on CRP despite the important role of for 
example haptoglobin in the immune response, bacterial translocation and O&NS pathways and a 
possible association between haptoglobin  polymorphism (Hp1 and Hp2) and depression [2,37-
39]. 
 As an exemplar of the broader issue, IL-6 binds to the IL-6 receptor (IL-6R), and the 
combined complex of IL-6 and IL-6R binds to glycoprotein (gp) 130, which triggers intracellular 
signaling. The protein gp130 is expressed ubiquitously on cells, but IL-6R is expressed only on a 
few cells. A soluble form of IL-6R (sIL-6R) also binds IL-6, and this complex also binds to 
gp130 on cells that don’t express the IL-6R; this mechanism is called IL-6 trans-signaling. IL-6 
trans-signaling is pro-inflammatory, while classic IL-6 signaling has anti-inflammatory or 
regenerative effects [40]. Thus, results on plasma IL-6 levels in isolation of the wider pathway 
without sIL-6R measurements does not allow one to make any inferences on the inflammatory 
consequences of IL-6 findings. IL-6 trans-signaling is probably increased in unipolar and bipolar 
depression and may underpin many of the immune-related pathways in depression [41,42]. 
Surprisingly, most if not all papers reporting on plasma IL-6 did not measure sIL-6R levels. All 
in all, this exemplar suggests that future research should focus on the broader pathways including 
IL-6 trans-signaling (and other cytokine networks) and other acute phase protein biomarkers in 
depression (zinc, albumin, transferrin, etc). More importantly, future research should consider 
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the role of the intracellular networks that control immune-inflammatory, O&NS, autoimmune 
and neuroprogressive pathways [8]. 
 Intracellular signaling pathways, such as glycogen synthase kinase-3 (GSK-3), nuclear 
factor-B (NF-B), Janus kinase / signal transducers and activators of transcription (JAK-
STAT), nuclear factor (erythroid-derived 2)-like 2 (Nrf-2) and the TLR2/4 complexes and other 
networks, modulate the immune-inflammatory, O&NS and neuroprogressive pathways [8]. 
Considering the broad-spectrum immune-inflammatory, O&NS and neuroprogressive state it 
may be hypothesized that these intracellular signaling networks are dysfunctional in depression 
[8]. There is, however, a lack of knowledge about how these networks critically interact with the 
immune-related pathways and/or undergo changes in activity or topology to lead to depression 
and to explain depression’s multiple comorbidities. None of these pathway and network markers 
exists in isolation and there are several complex and reciprocal interactions between the 
pathways and network molecules. Thus, it is needed to screen the whole system, i.e. pathways 
and networks, not the isolated components. Phrased differently, what is needed is to pinpoint the 
defects in the dynamic crosstalk between those pathways and networks. 
 Contemporary nosologic classifications of disorders derive from associations between 
pathological analyses and clinical syndromes and sometimes simple biomarkers [43]. This 
diagnostic strategy, however, has many limitations including lower sensitivity and specificity in 
correctly diagnosing the disorder [43]. With the growing new possibilities of –omics-based data 
sets, allowing researchers to measure and analyze network and pathway alterations, these older 
diagnostic strategies, combining syndromal phenomenology with simple biomarkers, will soon 
become a historical footnote [43]. As a comparison, a home inspection should focus on 
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evaluating the whole building not the bricks. The inspection should pinpoint major condition 
problems and hazardous defects in the building structure including rotten or cracked foundations, 
serious corrosion or roof structure issues, etc. Defect recognition and the consequent structural 
diagnosis are consequently used to repair or prevent structural building failures. 
 
Gaps and required improvements: new treatments 
 In psychiatry history the usual and logic path from “defect recognition” to “structural 
diagnosis” to “targeted repair” is actually reversed. First it is observed what clinically effective 
treatments do physiologically and then these medication effects are used as proxy 
pathophysiological markers for reverse engineering of other pharmaceuticals. One highly 
relevant example is the discovery and further development of the classical antidepressants drugs. 
Iproniazid was initially employed in the treatment of tuberculosis before it was discovered to be 
useful in the treatment of depression [44]. Also the discovery in the 1950s that imipramine, 
developed as an antihistamine, has antidepressant efficacy was by chance. The effects of these 
drugs on the monoaminergic systems were used to postulate the monoaminergic theories, 
including the serotonin hypothesis of depression [8]. This in turn fostered the (at first sight) 
pathophysiologically-guided development of selective serotonin reuptake inhibitors (SSRIs) 
[44]. Only later it was established that the efficacy of these drugs is much lower than first 
thought and probably only slightly better than placebo [1]. Thus, when all studies, either 
published or unpublished, submitted to the FDA were considered, the number of positive 
randomized controlled trials was only 51% [45,46]. This lack of effect of serotonergic drugs 
might be regarded as proof that antidepressants such as SSRIs cannot be regarded as “disease-
centred” drugs, i.e. drugs that normalize defects in 5-HT, which were thought to underpin the 
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pathophysiology of depression [45]. The proposed “drug-centred model” similarly attempts to 
explain the working mechanism of antidepressants, i.e. SSRIs increase 5-HT and therefore may 
improve depression via effects on other systems. Recently, we argued that the effects of 
antidepressants, including SSRIs, do not neatly fit either the serotonin disease-centred or the 
drug-centred models [8]. Indeed, antidepressants exert at least part of their clinical efficacy by 
attenuating inflammatory, immune (Th1), O&NS and neuroprogressive pathways 
[8,12,24,25,41,47-52]. Moreover, the efficacy of antidepressants may be augmented by 
administration of compounds targeting immune-inflammatory, O&NS and neuroprogressive 
pathways [4,8]. Nevertheless, for at least 30 years the 5-HT hypothesis of depression has guided 
research into the pathophysiology of depression and fostered the development of new, usually 
similar antidepressant drugs. Given the new possibilities offered by -omics-based and systems 
biomedicine methodologies, this old reversed path of discovery in psychiatric research should be 
augmented to make room for a more logical and pathophysiologically valid systems biomedicine 
based “path and drug discovery process” as we will explain below. 
  The role of multiple immune-related pathways in the onset and course of depression 
equally shows that it is too simplistic to consider that the inflammatory component in depression 
may be the only drug target [8]. There is as yet no compelling evidence that anti-inflammatory 
agents improve the O&NS, autoimmune and neuroprogressive pathways in depression. More 
importantly, many of the activated immune-inflammatory components in depression actually 
confer protection against an overzealous inflammatory response. Previously, we have described 
that depression is not only accompanied by a pro-inflammatory response but also by counter-
regulatory processes which tend to limit an overzealous immune-inflammatory response, i.e. the 
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compensatory anti-inflammatory reflex system (CIRS) [53]. For example, increases in sIL-1 
receptor antagonist (sIL-1RA) and sIL-2R indicate immune-inflammatory responses in 
depression, but are part of the CIRS downregulating the primary immune response. Induction of 
the TRYCAT pathway through CMI, inflammatory and oxidative processes confers protection 
against the primary immune-inflammatory and oxidative responses through lowered levels of 
tryptophan and increased levels of TRYCATs, such as kynurenine, and kynurenic and 
xanthurenic acid [54,55]. Some acute phase proteins, including haptoglobin, have anti-
inflammatory effects and act as antioxidants [37]. Elevated IL-6 levels may be anti-inflammatory 
and protective by increasing IL-1RA, IL-10 and glucocorticoid production [42,53]. 
Hypernitrosylation may downregulate intracellular signaling pathways including NF-B and the 
TLR4 complex and thus may have restorative effects [56]. IgM-mediated autoimmune responses 
directed to oxidative specific epitopes are part of natural autoimmune responses that actually 
have restorative effects [57]. Peroxisome proliferator-activated receptor-gamma (PPARγ), a 
transcription factor up-regulated in brain following stress exposure [58], has been directly 
implicated in the regulation of the neuroinflammatory response because several of its ligands 
(such as 15d-PGJ2) inhibit pro-inflammatory and O&NS mediators [59] as well as prevent 
excitotoxicity and energy compromise in the brain [60]. Thus, these CIRS responses have 
negative immunoregulatory, anti-inflammatory and/or antioxidant effects and may favor a Th2 or 
T regulatory responses thereby providing protection against immune-inflammatory and O&NS 
responses and neuroprogression [53]. Interfering with the equilibrium between the more 
detrimental and more protective forces may have unpredictable and unwanted effects. More 
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precise knowledge on the immune-inflammatory response and the CIRS in depression is needed 
before using drugs that interfere with this equilibrium. 
 Moreover, there are other caveats and lessons to learn. Anti-inflammatory drugs not only 
attenuate some specific inflammatory pathways but also unexpectedly drive other immune 
pathways to detrimental effects. A first example is COX-2 inhibition. Trials with selective COX-
2 inhibitors in depression were initiated before it was known that COX-2 expression is increased 
in depression and thus that COX-2 is a new possible drug target in depression [61,62]. It was 
known that selective COX-2 inhibitors may cause neuro-inflammation, aggravate Th1 responses, 
decrease the levels of key antioxidants, increase lipid peroxidation, cause bacterial translocation, 
damage mitochondria, and aggravate neuroprogression and cardiovascular disorder [61]. Thus, 
while COX-2 inhibitors may downregulate an initial increase in COX-2 expression, these drugs 
could have unwanted effects on other pathways associated with depression [61]. A possible 
cause of these effects may be that the inhibition of COX-2 also produces a decrease in the levels 
of 15-PGJ2, an endogenous ligand of transcription factor PPARγ. In this regard, a recent 
randomized double-blind placebo-controlled trial has shown that pioglitazone, a ligand of 
PPARγ, is a safe and effective adjunctive short-term treatment in patients with moderate-to-
severe depression even in the absence of metabolic syndrome and diabetes [63]. 
 Statins are another example. These drugs are thought to have a potential anti-depressive 
effect related to their anti-inflammatory properties [8,64]. A number of epidemiological studies 
show that statin use reduces depression risk [65,66], and the only randomized controlled trial to 
date suggests that lovastatin reduced symptoms of depression [67]. However, there are 
conflicting data suggesting that statins may actually worsen depression [68]. Tuccori et al. [69] 
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review that statins may cause many neuropsychiatric “side effects”, including depression, 
irritability, paranoia, alienation, sleep disorders, neurocognitive impairments and muscle 
weakness. These negative effects of statins could possibly be driven through effects on other 
pathways, including lipid and serotonin metabolism, the key antioxidant coenzyme Q10 and 
induction of autoimmune responses [68-70]. Infliximab, a monoclonal antibody directed against 
TNF  with anti-inflammatory and anti-oxidative effects, was recently shown to have 
antidepressive effects in patients with initially increased CRP levels [71]. Nevertheless, 
Etanercept and Infliximab, two anti-TNF agents used in juvenile arthritis and psoriasis, arthritis 
and inflammatory bowel disease in adults, have a long list of potentially severe side effects 
including depression, suicide, induction of mania, nervousness, anxiety, panic, aggressiveness, 
fatigue, sleep disorders [72-75]. While anti-TNF  agents have anti-inflammatory and 
antioxidative effects and reduce Th1 and Th17 responses these drugs may cause infections and 
autoimmune responses [76]. 
 Finally, it was reviewed that multi-targeting the abovementioned pathways, i.e. 
inflammation and Th1 activation and O&NS and neuroprogressive pathways may have 
therapeutic promise by exploiting the synergy between these pathways [8;77]. This is 
corroborated by reports that nutraceuticals with anti-inflammatory and anti-O&NS effects, which 
multi-target these pathways [e.g. ω3 PUFAs, zinc, N-acetyl cysteine and curcumin] may have a 
clinical efficacy in depression and reduce depressive-like behaviors in animal models [4,78-81]. 
Fond et al. [4], in their systematic review, conclude that of all possible anti-inflammatory 
treatments examined in depression ω3 PUFAs have the best benefit/risk ratio profile. Many other 
nutraceuticals with anti-inflammatory and anti-O&NS effects or their combinations (e.g. 
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coenzyme Q10, lipoic acid, green tea extract) are good drug candidates to be tested in 
randomized controlled trials because of their well known safety record and their properties multi-
targeting the pathways involved in depression [8]. Different drugs that multi-target the different 
abovementioned networks and pathways are already developed, e.g. kinase inhibitors and Nrf-2 
activators, but their efficacy and safety profile should first be screened in diverse (depression) 
models [8]. 
 The message is that without exact knowledge of the detailed pathways and networks 
involved in depression and the exact effects of classical anti-inflammatory drugs on these 
pathways/networks, the outcome is unpredictable [8,82]. Thus, new trials with anti-inflammatory 
drugs should be preceded and guided by detailed understanding of these agents on the networks  
and pathways [8,82]. Using “path and drug discovery processes” in combination with systems 
biomedicine methodologies allows one to better delineate these pathways and networks and the 
effects of different drugs on these pathways [82]. 
 
The way forward: path and drug discovery, omics-based assays  and systems biomedicine 
methodologies 
 State-of-the-art, omics-based assays, either high throughput or targeted, using 
standardized operational procedures, including network-focused Multi-Elisarrays and PCR 
Arrays measuring the NF-κB, JAK-STAT, GSK-3, Nfr2 and TLR networks in relation to 
immune-inflammatory, O&NS and neuroprogressive pathways, serotonin turnover, metabolic 
and endocrine functions and the microbiome should be carried out. This research should be 
translational including depressed patients with and without comorbid disorders and controls 
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(healthy volunteers and subjects with the comorbid disorders) and ideally include examination of 
plasma, cerebrospinal fluid (CSF) and stool microbiome samples and should examine –omics-
based biomarkers that assess these networks and pathways, including genomics, transcriptomics, 
proteomics and immunopreoteomics, metabolomics, epigenomics, etc. . Proof of –omics-based 
research in patients should be checked in post-mortem brain in both patients and control groups. 
 Consequently, the complex systems medicine mechanisms underpinning depression and 
comorbid disorders and the sex-and gender-related differences, according to the gendered 
innovations approach [83] should be delineated using system medicine based methodologies 
[42,84-90]. Systems biomedicine approaches performed on omics-based high throughput and 
targeted measurements will likely be essential to a) unravel the non-linear and complex 
interactions between the networks, pathways, multifactorial trigger factors and comorbid 
disorders; b) pinpoint the molecular defects in these networks and pathways that cause 
depression and maintain the comorbid disorders; and c) develop a mathematical model that 
delineates the molecular signature and new biomarkers of depression. The identification of the 
peripheral and central cell signaling networks and immune-inflammatory, O&NS and 
neuroprogressive pathways that cause depression and maintain the comorbid disorders by means 
of systems biomedicine methods is likely to be a much needed advance compared with the 
present state of the art, which only considers the role played by a few inflammatory biomarkers. 
Visualization, machine learning and data mining tools should be used to explore and interpret the 
networks and pathways and a causal reasoning approach [86,87] should be applied to identify 
and rank trigger factors for depression and its phenotypes, including melancholic, physio-
somatic, anxiety and atypical symptoms, suicidal ideation and behavior, neurocognitive disorders 
and staging characteristics. To prioritize trigger factors and delineate new intervention strategies, 
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existing knowledge databases, consisting of pre-compiled information on molecular and pathway 
analysis (e.g. the ResNet databases), could be used. Causal reasoning analysis and dedicated 
visualization tools can be used to delineate trigger and pathophysiological factors as well as new 
drug targets for therapeutic intervention [88,89]. State-of-the-art bioinformatic analyses could be 
employed to model the complex dynamic processes and predict the phenotypic effects of 
perturbations in the networks/pathways using their static structure [90]. Drug discovery 
processes could consequently identify the effects of new putative antidepressants. Towards this 
end, different families of new and selective kinase inhibitors, e.g. p38 MAPK, JAK 1,-2,-3 
inhibitors and GSK-3 inhibitors, Nrf-2 activators and TLR2/4 antagonists should be tested in 
immune-inflammatory depression models. 
 All in all, the combination of path and drug discovery processes, omics-based assays  and 
systems biomedicine methodologies will enable the generation of new systems biomedicine 
models in depression, to visualize the complex architecture of these networks and pathways 
whose alterations cause depression and maintain or worsen the comorbid disorders. Based on 
these assays, new omics-based biomarker tools may be developed that will be useful to diagnose 
depression. The systems biomedicine approach will hopefully delineate new drug targets and 
new combinatorial treatments that will aid in the prevention and the treatment of depression also 
when comorbid with (auto)immune or neuro-inflammatory disorders. 
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